產品
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
A feature on the Moderna and Merck cancer vaccine breakthrough, framed as success after a century of failed attempts at cancer vaccines.
文章預覽
By Michael Erman and Julie Steenhuysen Aug 28 (Reuters) – Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant celebrating a friend’s birthday late on August 13 when he got the call. An mRNA cancer vaccine the company had been developing with Merck had hit its mark — the first success of a therapeutic cancer vaccine in late-stage testing after more than 100 years of failed attempts. Cancer experts hailed it as the beginning of an era of custom-made vaccines that train the immune system to fight an individual patient’s cancer. In a trial of more than 1,000 patients with localized mela…